- Home
- BFS vs APLT Comparison
BFS vs APLT Comparison
Compare BFS & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFS
- APLT
- Stock Information
- Founded
- BFS 1993
- APLT 2016
- Country
- BFS United States
- APLT United States
- Employees
- BFS N/A
- APLT N/A
- Industry
- BFS Real Estate Investment Trusts
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- BFS Real Estate
- APLT Health Care
- Exchange
- BFS Nasdaq
- APLT Nasdaq
- Market Cap
- BFS 934.4M
- APLT 128.0M
- IPO Year
- BFS 1993
- APLT 2019
- Fundamental
- Price
- BFS $38.27
- APLT $0.90
- Analyst Decision
- BFS Strong Buy
- APLT Buy
- Analyst Count
- BFS 1
- APLT 7
- Target Price
- BFS $45.50
- APLT $6.10
- AVG Volume (30 Days)
- BFS 42.2K
- APLT 8.4M
- Earning Date
- BFS 02-27-2025
- APLT 11-07-2024
- Dividend Yield
- BFS 6.16%
- APLT N/A
- EPS Growth
- BFS 10.72
- APLT N/A
- EPS
- BFS 1.85
- APLT N/A
- Revenue
- BFS $267,606,000.00
- APLT N/A
- Revenue This Year
- BFS N/A
- APLT N/A
- Revenue Next Year
- BFS $6.21
- APLT $2,664.24
- P/E Ratio
- BFS $20.73
- APLT N/A
- Revenue Growth
- BFS 5.83
- APLT N/A
- 52 Week Low
- BFS $34.87
- APLT $0.77
- 52 Week High
- BFS $42.39
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- BFS 36.68
- APLT 19.46
- Support Level
- BFS $37.98
- APLT $0.78
- Resistance Level
- BFS $39.15
- APLT $0.90
- Average True Range (ATR)
- BFS 0.77
- APLT 0.12
- MACD
- BFS -0.10
- APLT 0.26
- Stochastic Oscillator
- BFS 10.82
- APLT 20.97
About BFS Saul Centers Inc.
Saul Centers Inc is a self-managed real estate investment trust which invests in, operates, and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: shopping centers, which contribute the maximum portion of total revenue; and mixed-use properties. Maximum tenants include grocery stores, discount department stores, and drug stores.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.